2. Opioid Analgesic Narcotic
opioid (mu) receptor agonist, and an N-methyl-D receptor
(NMDA), dual mechanism
Reserved for moderate to severe pain
Pain not relieved by non-narcotics
Changes how brain and nervous system responds to
pain
3. Leading disease of adult in Western World
Studies indicate those with ulcerative colitis over 10
years have 3-fold increase of developing colon
cancer
Treatment chemotherapy, radiation, pain
management
Colon Cancer account for 9-10%of all deaths in the
U. S.
4. Activates opioid receptors on surface of cancer cell
Increased by grapefruit
Decreased by Phenobarbital
MAO inhibitor stopped within 14 days
5. Prolonged QT interval
CNS depression
EKG required 24-72 hours after start or upon
increase of dosing
Constipation
Accumulation side effects:
Sedation
Nausea
Respiratory depression
6. 90% Bioavailability
Vary extremely among individuals
Caution in elderly cancer patients taking multiple
medications
Limit medications that inhibit or stimulate the P450
system, in order to avoid interactions and
undesirable side effects
7. Bound to plasma tissue protein, metabolized by:
The NMDA receptor is activated when glutamate
and glycine (or D-serine) binds to it when activated
it allows positively charged ions to flow through the
cell membrane.
Methadone is metabolized by the CYP3A4 and
CYP-450 enzyme system and is a substrate for the
P-Glycoprotein efflux protein in the intestine and
brain
8. Interdisciplinary environment
Evidenced-based best practice guidelines
Methadone prescribing guidelines
Trusting therapeutic relationship
Patient education
9. Goal for elderly cancer patient to have decreased
pain and improved quality of life
Appropriate assessment tools for elderly
May require lower dose of methadone
Monitor comorbidities
Monitor polypharmacy
10. Arcangelo, V. P., Wilbur, V. F., (2017). Principles of Pharmacology in Pain Management. In V. P. Arcangelo (Eds.),
Pharmacotherapeutics for advanced practice a practical approach (4th ed.). Philadelphia, PA: Wolters Kluwer.
Arcangelo V P Peterson A M Wilbur V Reinhold J A 2017 Pharmacotherapeutics for Advanced Practice A Practical
Approach20171025105455713663697Arcangelo V P Peterson A M Wilbur V Reinhold J A 2017 Pharmacotherapeutics for
Advanced Practice A Practical Approach Czosnowski, Q. A., Whitman, C. B., Aykroyd, L., (2017). Principles of
Pharmacology in Pain Management. In V. P. Arcangelo (Eds.), Pharmacotherapeutics for advanced practice a practical
approach (4th ed.). Philadelphia, PA: Wolters Kluwer.
Division of Unintentional Injury Prevention National Center for Injury Prevention and ControlCenters for Disease Control and
Prevention. (2013). Challenges in the Management of Opioid-Using Patients in Emergency Departments. Retrieved from
http://www.jointcommission.org/assets/1/18/Updated_approved_CDC_slides_to_post_
ED_Opioid_Use_webinar_in_PDF.pdf
ED_Opioid_Use_webinar_in_PDF.pdf
Lugo, R. A., Satterfield, K. L., Kern, S.E. (2005). Pharmacokinetics of methadone. PubMed, 19(4), 13-24. Retrieved from
Peirano, G.,Mammana,G. Bertolino, M., Pastrana, T., Vega, G., Russo, J., & ... Ruggiero, R. (2016). G., Mammana, G., Bertolino,
M., Pastrana, T., Vega, G., Russo, J., & Ruggiero, R. (2016). Methadone as first-line opioid treatment for cancer pain in a
developing country palliative care unit. Supportive Care In Cancer, 24(8), 3551-3556. doi:10.1007/s00520-016-3191-5
https://www.ncbi.nlm.nih.gov/pubmed/16431829
Schreiber, J. A. (2013). We've come a long way: A review of cancer pain management. Oncology Nursing Forum, 40(2), 106-108.
Virshup, D. M., (2010). Biology, Clinical Manifestations, and Treatment of Cancer. In K. H. McCane (Eds.), Pathophysiology: The
Biologic Basis for Disease in Adults and Children, 6th Edition. [Pageburstl]. Retrieved from Afsharimani, B., Kindl, K.,
Good, P., & Hardy, J. (2015). Pharmacological options for the management of refractory cancer pain-what is the evidence?.
Supportive Care In Cancer, 23(5), 1473-1481. doi:10.1007/s00520-015-2678-9